Significant improvement in signs and symptoms of meibomian gland dysfunction were achieved with AZR-MD-001, a topical ointment, thus meeting the primary endpoints of the drug’s phase 2 trial, Azura Ophthalmics announced in a press release.
In the multicenter, double-masked, vehicle-controlled, integrated analysis of four separate phase 2 studies, safety and efficacy of AZR-MD-001 were analyzed for doses of 0.1%, 0.5% and 1% in 95 patients.
Statistically significant reduction of symptoms as measured by Ocular Surface Disease Index scores was demonstrated in the 0.5% and 1% groups (both P <
Uncategorized